CANNABIX TECHNOLOG (OTCMKTS:BLOZF) Delivers 50% Gains For Our Subscribers; More To Come?

Readers will remember well our articles about CANNABIX TECHNOLOG (OTCMKTS:BLOZF), which develops marijuana breathalyzers. Company LogoWe said that the company was releasing good news about the results of its human subject testing. Additionally, we mentioned that the management seemed to have a lot of expertise in the field.The company was, in our opinion, a very interesting name to follow.As of today, we are very proud of having identified BLOZF as a top pick for our subscribers..The share price spiked in November. From $0.45, the price increased to cross the $0.70 share price level. Have a look at it: 1 year chart for BLOZFIn addition, more than one million shares changed hands. We believe that this fact clearly shows that many in the market are now giving due consideration to the company's developments. We appreciate that we informed our readers long time ago about this opportunity.Have a look at it: 1 month chart for BLOZFBefore we explain what's going on, we are revisiting for a minute the business model of BLOZF. Cannabix develops breath testing technologies "to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally."Watch the following video:

SourceRecent DevelopmentsA lot of things happened after our last article. The following are the most significant.On May 25, 2017, the company released that Dr. David Hasman had been added to the team. He will be responsible for initiating trials in British Columbia.Like other members of the management, he has an interesting profile. He has expertise in the LC/MS/MS method for fentanyl and analogues for the B.C. Provincial Toxicology Centre in Vancouver. Additionally, he holds a PhD in Chemical Physics from the University of California and was a postdoctoral fellow at the University of British Columbia. Furthermore, he has worked for big companies, like Hewlett-Packard and Agilent Technologies, and has taught chromatographic based analysis at BCIT and University of British Columbia.How will he help the company?He has large expertise in toxicology, and forensic mass spec. Thus, he is an ideal person to run the trials of the Cannabix Marijuana Breathalyzer prototype.There is more.On July 31, 2017, the company announced the development of Beta 3.0 Marijuana Breathalyzer and provided an update. It was reminded that the new version is based on its FAIMS- (field asymmetric waveform ion mobility spectrometry) technology. Additionally, it was released that it includes new advancements in the design and commercial capabilities of the device. The following improvements were noted among some others:- Dynamic testing is now allowed- Easier configurability- Specialized flow-through heat exchanger technology to stabilize breath temperature in cold as well as humid temperature.- Real time breath analysis for concentrations of CO2, humidity, temperature and flow-rate to better detect delta-9-tetrahydrocannabinol in human breath.Additionally, it was highlighted that the company has increased its testing capabilities with investment in a state-of-the art lab space in Vancouver, B.C., and acquired a Thermo Scientific mass spectrometer and related equipment.Finally, discussions with a U.S. based institution with a large user group and enhanced testing environment were noted. This may be a great catalyst for the stock if an agreement is signed. Be alert on it.But the most significant was still to come.On November 7, 2017, the company release that it had filed several Patent Cooperation Treaty applications related to product development innovations. The news excited the market, which reacted by pushing up the share price. We agree with the vision of the market. New patent applications may return revenues in the future and stock appreciation.It was noted that the use of Ignition Interlock Device is being required by many countries when the driver has been convicted of driving under the influence of alcohol, and drugs. This device is installed to confirm that the driver is not impaired before the vehicle starts.In some states in the U.S. and Canada, this condition has been approved. Additionally, more and more families are choosing to install this type of device to protect young drivers.We believe that these developments are great news for the company, which should see a big increase in revenues if these systems become widely used.Additionally, it was note that the “Beta 3.0” prototype is 95% complete and the company will commence testing with this latest device shortly. We believe that market participants are seeing that the company will report the first revenues soon and decided to push up the share price.Furthermore, new technological innovations have been added recently:

"A feedback loop to the dielectric barrier discharge (“DBD”) ion source which allows a shorter time to stable ionization with a conventional battery source resulting in a quicker start-up time." Source

ConclusionCurrently trading with a market cap of $54 million, BLOZF is an exciting story among small caps. With CAD$3.1 in cash, no debt and only CAD$0.1 in total liabilities, it seems that the company is very well financed to continue its innovative trajectory.To sum up, BLOZF has a lot of potential, projects, and cash. The stock has already delivered 50% gains and we don't see why the move higher can't continue. The market for a marijuana breathalyzer is enormous.Be sure to check out our coverage on BLOZF!We will be updating our subscribers as soon as we know more. For the latest updates on BLOZF, sign up below!Image courtesy of Mark Fingerhut via FlickrDisclosure: We have no position in BLOZF and have not been compensated for this article.